Nima Farzan
CIK 1808296 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-08
Nima Farzan is a CHIEF EXECUTIVE OFFICER who has filed 13 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $28.2K of KROS on Jun 8, 2026. Across all open-market trades the lifetime net is −$28.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $99.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$99.1K
2
13
-$28.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 9,767 | $10.15 | $99.1K | -$28.2K | 8 | 2026-06-08 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Chief Executive Officer | — | $2.65 | — | $0 | 4 | 2023-02-15 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | KROS | Sell (S) | −2,625 | -$28.2K | EDGAR |
| 2026-06-05 | KROS | Grant (A) | +7,142 | $0 | EDGAR |
| 2025-06-06 | KROS | Grant (A) | +5,250 | $0 | EDGAR |
| 2024-06-03 | KROS | Grant (A) | — | $0 | EDGAR |
| 2024-04-05 | — | Disp (D) | −2,186 | $0 | |
| 2023-06-08 | KROS | Grant (A) | — | $0 | EDGAR |
| 2023-02-15 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-14 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | KROS | Grant (A) | — | $0 | EDGAR |
| 2022-02-15 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |